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reamble
ver the past decade, there has been an increasing awareness
at the quality of medical care delivered in the United States,
fined as the delivery of effective, timely, safe, equitable,
ficient, and patient-centered medical care, has the potential
r improvement (1).
Consistent with this focus on healthcare quality, the Amer-
an College of Cardiology Foundation (ACCF) and the
merican Heart Association (AHA) have taken a leadership
le in defining “what works in medicine” with their ACCF/
HA guidelines statements, as well as in developing perfor-
ance measures that define what should or should not be
ne in the care of patients with cardiovascular disease
able 1).
The ACCF/AHA Task Force on Performance Measures
as originally formed in February 2000 and was charged
ith identifying the clinical topics appropriate for the devel-
ment of performance measures and with assembling writ-
g committees composed of clinical and methodological
perts. When appropriate, these writing committees have
cluded representation from other organizations involved in
e care of patients with the condition of focus. The writing
mmittees are informed about the methodology of perfor-
ance measure development (2) and are instructed to con-
ruct measures for broad use that meet these criteria. The
riting committees also are directed to strive to create
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igned with national standards so as to promote harmony
ong measures.
Performance measures can include structural, process, or
tcome measures (11). Although implementation of mea-
res of outcomes and efficiency is currently not as well
tablished as that of process measures, it is expected that
ch measures will become more pervasive over time.
Performance measures also vary in the degree of evidence
pporting their use and in the information available about
w their implementation may affect provider behaviors.
herefore, it is within the scope of the writing committee’s
sk to comment, when appropriate, on the strengths and
mitations of external reporting for a particular cardiovascu-
r disease state or patient population. Thus, the metrics
ntained within this document are categorized as either
erformance measures” or “quality measures.” Performance
easures are those metrics that the writing committee desig-
tes as appropriate for use for both quality improvement and
ternal reporting. In contrast, quality measures are those
propriate for the purposes of quality improvement but not
r external reporting until further validation and testing are
rformed.
All measures have limitations and pose challenges to
plementation that could result in unintended consequences.
he manner in which these issues are addressed is dependent
several factors, including the data collection method,
rformance attribution, baseline performance rates, incen-
ves, reporting methods used, and the incentives linked to
ese reports. The ACCF/AHA encourages those interested in
plementing these measures for purposes beyond quality
provement to work with the ACCF/AHA to consider these
mplex issues in pilot implementation projects, to assess
mitations and confounding factors, and to guide refinements
the measures to enhance their utility for these additional
rposes.
By facilitating measurements of cardiovascular healthcare
ality, ACCF/AHA performance measurement sets may
rve as vehicles to accelerate appropriate translation of
ientific evidence into clinical practice. These documents are
tended to provide practitioners and institutions that deliver
re with tools to measure the quality of their care and
entify opportunities for improvement. It is our hope that
plication of these performance measures will provide a
echanism through which the quality of medical care can be
easured and improved.
The present set of measures breaks important ground for
rformance measurement: First, as opposed to many measures
cused on acute disease treatment in the hospital setting, these
e focused on primary and secondary prevention in the ambu-
tory setting. Second, the present measures address not only
hether important cardiac risk factors such as hypertension and
ids are “treated” but whether these are “controlled” to target
als. Achieving such control requires both clinicians and their
tients to fulfill their respective roles. The clinician must
entify a risk, implement appropriate intervention, monitor the
sponse, and then further modify care to reach target goals. The
tient too has an important part in reaching success, including
eping appointments, modifying his or her lifestyle, and adher- tag to prescribed therapies. Finally, these performance measures
phasize patient-focused functional outcomes. They stress the
ed to assess patient angina and functional symptoms but also
develop treatment plans to improve these outcomes.
Eric D. Peterson, MD, MPH, FACC, FAHA
Chair, ACCF/AHA Task Force on Performance Measures
. Introduction
he ACCF/AHA/American Medical Association–Physician
onsortium for Performance Improvement (AMA–PCPI)
oronary Artery Disease and Hypertension Performance
easures Writing Committee (the writing committee) was
arged with revising the ACCF/AHA/AMA–PCPI Chronic
oronary Artery Disease and Hypertension performance
easures sets, which were published in 2005 (4,5). The
rpose of the present effort is to provide updated measures
at can be used to improve care for patients with coronary
tery disease (CAD) and hypertension.
Recognizing that each measure may impose a burden on
oviders, the writing committee sought to focus on those areas
ith the most potential for impact, where there was the strongest
nsensus about the best practice, and where the likelihood for
intended harm was lowest. Moreover, the group sought as
uch as possible to keep the measures straightforward, aligned
hen appropriate with measures developed by others, and
inically sensible, giving the clinician the latitude for judgment
out the appropriateness of an intervention when such latitude
justified. Finally, the writing committee sought to adhere to the
ganizations’ previously published methodology for creating
rformance measures (2,12).
This updated measure set addresses care in the outpatient
tting exclusive of the emergency department. Many
ideline-recommended processes were not translated into
easures. Decisions about measures to include were based on
any factors. Common considerations were the complexity
the guideline recommendations on which the measures
ere based (potentially making translation difficult) and the
asibility of collecting the required data. This document is
tended to supersede the prior CAD and hypertension
rformance measures set (4,5).
The members of the writing committee included clinicians
ecializing in cardiology, internal medicine, family medi-
ne, hospital medicine, and advanced practice nursing, as
ell as individuals with expertise in performance measure
velopment, implementation, and testing. The writing com-
ittee also included patient/consumer representatives and a
yer representative. The writing committee had representa-
on from the American Academy of Clinical Endocrinolo-
sts, the American Association of Cardiovascular and Pul-
onary Rehabilitation, American Academy of Family
hysicians, the American College of Emergency Physicians,
e American College of Radiology, the American Geriatrics
ociety, the American Nurses Association, the American
ociety of Health-System Pharmacists, the Society of Hospi-
l Medicine, and the Society for Thoracic Surgeons.
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July 12, 2011:316–36 Performance Measures for CAD and HypertensionIn this updated measure set, the writing committee presents
measures, including 2 new measures and 5 revised
easures, all of which are intended only for the ambulatory
utpatient) setting. A summary of the new measures set is
esented in Table 2.
.1. Scope of the Problem
AD and hypertension are major and growing public health
oblems in the United States. See the ACCF/AHA/AMA–
CPI 2011 chronic stable coronary artery disease (4a) and
pertension (5a) performance measurement sets, which are
th available on the PCPI Web site at http://www.ama-
sn.org/apps/listserv/x-check/qmeasure.cgi?submitPCPI,
r a detailed discussion of the scope of the problem and
portunities for improving the quality of care provided to
tients with these conditions.
.2. Disclosure of Relationships
ith Industry and Other Entities
he work of the writing committee was sponsored exclu-
vely by the ACCF, the AHA, and the AMA–PCPI, without
mmercial support. Writing committee members volun-
ered their time for this effort. Meetings of the writing
mmittee were confidential and attended only by committee
embers and staff from the ACCF, AHA, AMA–PCPI, The
int Commission, and the National Committee on Quality
ssurance (NCQA) to promote harmonization across similar
easure sets, as described further in later sections. Writing
mmittee members were required to declare in writing all
lationships with industry relevant to this topic. Less than
% of the writing committee membership has relationships
ith industry relevant to this topic, in accordance with
andard requirements of the ACCF and AHA. Please see
ppendix A for relevant writing committee relationships with
dustry. In addition, Appendix B includes relevant relation-
ble 1. ACCF/AHA Performance Measure Sets
Topic Original Publication Date
ronic heart failure (3) 2005 ACC/A
ACC/A
ronic stable coronary artery
sease (4)
2005 ACC/A
pertension (5) 2005 ACC/A
-elevation and non–ST-elevation
yocardial infarction (6)
2006 ACC/A
rdiac rehabilitation (7) 2007 AACVP
rial fibrillation (8) 2008 ACC/A
imary prevention of CVD (9) 2009 ACCF/
ripheral artery disease (10) 2010 ACCF/
rcutaneous coronary intervention 2012* ACCF/
rdiac imaging 2012* ACCF/
AACVPR indicates American Association of Cardiovascular and Pulmonary Reha
undation; ACR, American College of Radiology; AHA, American Heart Assoc
sociation–Physician Consortium for Performance Improvement; SCAI, Society
M, Society for Vascular Medicine; SVN, Society for Vascular Nursing; and SV
*Planned publication date.ips with industry for all peer reviewers of this document. op.3. Review and Endorsement
etween February 9, 2010, and March 13, 2010, the ACCF/
HA/AMA–PCPI 2011 Performance Measures for Adults
ith Coronary Artery Disease and the 2011 Performance
easures for Adults With Hypertension underwent a 30-day
blic comment period. During this time, ACCF, AHA, and
MA–PCPI members, as well as other health professionals
d members of the general public, had an opportunity to
view and comment on the draft document in advance of its
nal approval and publication. An official peer and content
view of the full document was also conducted, with 2 peer
viewers nominated by the ACCF and 1 reviewer nominated
the AHA. Additional comments were sought from clinical
ntent experts and performance measurement experts.
The ACCF/AHA/AMA–PCPI 2011 Performance Mea-
res for Adults With Coronary Artery Disease and Hyper-
nsion was adopted by the respective boards of the ACCF
d AHA and approved by the AMA–PCPI in January 2011.
hese measures will be reviewed for currency once annually
d updated as needed. They should be considered valid until
ther updated or rescinded by the ACCF/AHA Task Force on
erformance Measures and the AMA–PCPI.
. Methodology
he development of performance measures involves identifi-
tion of a set of measures targeted toward a particular patient
pulation, observed over a particular time period. To
hieve this goal, the ACCF/AHA Task Force on Perfor-
ance Measures has outlined and published a methodology
sequential tasks required for the development of process-
-care measures as well as for outcomes measures suitable
r public reporting (2,11). In addition, the AMA–PCPI has
veloped a Work Group Charge that outlines the process
eps that should be followed by writing committees devel-
ring Organizations Status
patient measures Currently undergoing update
I—outpatient measures Currently undergoing update
I Updated 2011 (4a)
I Updated 2011 (5a)
Updated 2008 (6a)
AHA Updated 2010 (referral measures only) (7a)
I . . .
. . .
R/SCAI/SIR/SVM/SVN/SVS . . .
AI/PCPI/NCQA . . .
R/PCPI/NCQA . . .
; ACC, American College of Cardiology; ACCF, American College of Cardiology
CQA, National Committee for Quality Assurance; PCPI, American Medical
iac Angiography and Interventions; SIR, Society for Interventional Radiology;
ty for Vascular Surgery.Partne
HA—in
HA/PCP
HA/PCP
HA/PCP
HA
R/ACC/
HA/PCP
AHA
AHA/AC
AHA/SC
AHA/AC
bilitation
iation; N
for Card
S, Socieing performance measures (13). The following sections
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Performance Measures for CAD and Hypertension July 12, 2011:316–36tline how these methodologies were applied by the present
riting committee.
.1. Identifying Clinically Important Outcomes
o guide the selection of measures for inclusion in the measure
t, the writing committee sought to identify outcomes that are
eaningful to patients with CAD or hypertension and the
ructures or processes recommended by practice guidelines that
e most strongly associated with those outcomes. The processes
which measures were based include management of risk
ctors, identification of effective therapeutic options in eligible
tients, and accurate and appropriate evaluation of symptoms to
ble 2. 2011 ACCF/AHA/AMA–PCPI Coronary Artery Disease and
Measure
ronary artery disease
1. Blood pressure control Percentage of patients aged 18 years wit
a blood pressure 140/90 mm Hg, OR wh
2 antihypertensive medications during the
2. Lipid control Percentage of patients aged 18 years wit
an LDL cholesterol result 100 mg/dL, OR
care to achieve LDL cholesterol 100 mg/
3. Symptom and activity
assessment
Percentage of patients aged 18 years wit
there are documented results of an evaluat
symptoms‡ in the medical record
4. Symptom
management†
Percentage of patients aged 18 years wit
results of an evaluation of level of activity,
appropriate management of anginal sympto
symptoms, OR evaluation of level of activity
documented to achieve control of anginal s
5. Tobacco use:
screening, cessation,
and intervention
Percentage of patients aged 18 years wit
screened for tobacco use AND received tob
6. Antiplatelet therapy Percentage of patients aged 18 years wit
prescribed aspirin or clopidogrel
7. Beta-blocker therapy:
prior myocardial
infarction or left
ventricular systolic
dysfunction
Percentage of patients aged 18 years wit
have prior myocardial infarction or a curren
8. ACE inhibitor/ARB
therapy: diabetes or
left ventricular systolic
dysfunction
(LVEF 40%)
Percentage of patients aged 18 years wit
have diabetes or a current or prior LVEF 
9. Cardiac rehabilitation
patient referral from
an outpatient setting
(7,12)†
All patients evaluated in an outpatient settin
infarction, coronary artery bypass graft surg
stable angina and have not already particip
event/diagnosis and are referred to such a
pertension
1. Blood pressure control Percentage of patients aged 18 years wit
pressure 140/90 mm Hg, OR who have a
medications during their most recent office
*Please refer to the complete measures for comprehensive information, inclu
†New measure.
‡Includes assessment of anginal equivalents.
ACCF indicates American College of Cardiology Foundation; ACE, angiotensin-
sociation–Physician Consortium for Performance Improvement; ARB, angioten
w-density lipoprotein; LVEF, left ventricular ejection fraction; and PCI, percutaide treatments. A complete list of the desirable outcomes Centified by the writing committee and how they relate to the
oposed process measures is included in the measure specifi-
tions, which are available on the PCPI Web site at http://
ww.ama-assn.org/apps/listserv/x-check/qmeasure.cgi?submit
PI (4a,5a).
.2. Dimensions of Care
iven the multiple measurable domains of providing care, the
riting committee identified and explicitly articulated the
levant dimensions of care that should be evaluated. As part
the methodology, each potential performance measure was
tegorized into its relevant dimension of care (Table 3).
rtension Measurement
Description*
nosis of coronary artery disease seen within a 12-month period who have
blood pressure 140/90 mm Hg and were prescribed
ecent office visit
nosis of coronary artery disease seen within a 12-month period who have
ve an LDL cholesterol result 100 mg/dL and have a documented plan of
ding, at a minimum, the prescription of a statin
nosis of coronary artery disease seen within a 12-month period for whom
vel of activity AND an evaluation of presence or absence of anginal
nosis of coronary artery disease seen within a 12-month period and with
h an evaluation of presence or absence of anginal symptoms‡, with
luation of level of activity and symptoms includes no report of anginal
mptoms includes report of anginal symptoms, and a plan of care is
s)
nosis of coronary artery disease seen within a 12-month period who were
ssation counseling if identified as tobacco users
nosis of coronary artery disease seen within a 12-month period who were
nosis of coronary artery disease seen within a 12-month period who also
r LVEF 40% who were prescribed beta-blocker therapy
nosis of coronary artery disease seen within a 12-month period who also
d who were prescribed ACE-inhibitor or ARB therapy
within the previous 12 months have experienced an acute myocardial
I, cardiac valve surgery, or cardiac transplantation, or who have chronic
an early outpatient CR or secondary prevention program for the qualifying
nosis of hypertension seen within a 12-month period who have a blood
ressure 140/90 mm Hg and were prescribed 2 antihypertensive
easure exceptions (4a,5a).
ng enzyme; AHA, American Heart Association; AMA–PCPI, American Medical
eptor blocker; CAD, coronary artery disease; CR, cardiac rehabilitation; LDL,
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July 12, 2011:316–36 Performance Measures for CAD and Hypertensionon of areas in which evidence was lacking and prevented
plication of measures within the set. Diagnostics, patient
ucation (including prognosis and etiology), treatment, self-
anagement, and monitoring of disease status were selected
the relevant dimensions of care for CAD and hypertension
rformance measures.
In addition, to ensure the measure set is as comprehensive
possible, the writing committee also evaluated the potential
easures against the Institute of Medicine domains of health-
re quality (safety, effectiveness, patient-centeredness, time-
ness, efficiency, and equity) (1). While focusing primarily
processes of care, the writing committee also considered
easures of structures of care and outcomes for CAD (e.g.,
mptom management and lipid management) and for hyper-
nsion (e.g., blood pressure control). Although the writing
mmittee does not endorse any particular measure devel-
ed by others and believes that all measures should be used
quantify the full spectrum of relevant healthcare dimen-
ons, the measures proposed in this set are intended to
mplement existing National Quality Forum (NQF)–en-
rsed CAD outcome measures, such as the HealthPartners
timally managed modifiable cardiac risk factor measure
4), and NQF-endorsed hypertension outcome measures,
ch as the NCQA hypertension control measure (15,16).
.3. Literature Review
he writing committee developed this revised measurement set
the basis of several clinical practice guidelines and did not
rform an independent assessment of the evidence itself.
urthermore, the writing committee followed the methodology
ecified in the ACC/AHA document on developing process
easures (2) and in the PCPI position statement on the evidence
se required for measures development (17). The practice
idelines and statements that provided the basis for these
ble 3. 2011 ACCF/AHA/AMA–PCPI Coronary Artery Disease and
imensions of Care Measures Matrix
Measure Name Diagnostics
ronary artery disease
1. Blood pressure control ✓
2. Lipid control ✓
3. Symptom and activity assessment
4. Symptom management
5. Tobacco use: screening, cessation, and intervention ✓
6. Antiplatelet therapy
7. Beta-blocker therapy: prior myocardial infarction
8. ACE inhibitor/ARB therapy: diabetes or
left ventricular systolic dysfunction (LVEF 40%)
9. Cardiac rehabilitation patient referral from an outpatient
setting
pertension
1. Blood pressure control ✓
*Although no current measures exist for this dimension, future development
ACCF indicates American College of Cardiology Foundation; ACE, angiotensin-
sociation–Physician Consortium for Performance Improvement; ARB, angioteneasures can be seen in Table 4. reTo avoid duplication of efforts and to harmonize with other
tional measures as much as possible, the writing committee
so reviewed existing CAD measures, including those devel-
ed by HealthPartners, the Agency for Health Research and
uality (30), the Institute for Clinical Systems Improvement
6,31), and the Veterans Health Administration (32), as well as
pertension outcome measures developed by Institute for
linical Systems Improvement (33), NCQA (15,16), and the
eterans Health Administration (32).
.4. Definition and Selection of Measures
xplicit criteria exist for the development of process perfor-
ance measures so that they accurately reflect the quality of
re, including a strong evidence base; quantification of the
merator and denominators of potential measures; and
aluation of the interpretability, applicability, and feasibility
the proposed measure (2). The writing committee sought to
entify measures for which there was strong evidence for
d clear consensus about their importance in the care of
AD and hypertension patients and that is linked to improved
tcomes.
In addition to analyzing the updated guideline recommen-
tions, the writing committee reviewed other clinical guid-
ce documents, as detailed below, as well as all available
formation on gaps in care and unexplained variations in
re for CAD and hypertension patients. The writing com-
ittee also reviewed data on feasibility, reliability, and
ception reporting available from implementation of a sub-
t of the 2005 measures (34–38). The writing committee
plied a patient-centric approach to identify areas where
w measures or revisions to the 2005 measures might be
eded. As part of this process, the writing committee also
nsidered whether any of the 2005 measures should be
tired. After extensive discussion and additional literature
rtension Performance Measurement Sets:
Patient
ducation* Treatment Self-Management*
Monitoring of
Disease Status
✓
✓
✓
✓ ✓
✓ ✓ ✓
✓
✓
✓
✓ ✓
✓
mine how to address this dimension of care.
ng enzyme; AHA, American Heart Association; AMA–PCPI, American Medical
ceptor blockers; and LVEF, left ventricular ejection fraction.Hype
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Performance Measures for CAD and Hypertension July 12, 2011:316–36easures included in the 2005 CAD and hypertension out-
tient measure sets. The comparison of the 2005 and 2011
easures is shown in Table 5.
All measures were designed to assess quality of care in
propriate patients across a variety of outpatient care settings
d care teams and to support achievement of the desirable
tcomes identified. The measures also were designed to allow
r the exclusion of patients with contraindications to the process
care or other valid reasons for not including them in the
easure. In defining the measure exceptions, the writing com-
ittee was guided by the AMA–PCPI Recommendations for
pecification and Categorization of Measure Exclusions (17), as
scussed further below.
The writing committee evaluated the potential new and
vised measures against the ACCF/AHA attributes of per-
rmance measures (Table 6) to reach consensus on which
easures should advance for inclusion in the final measure
t and whether to designate any of the measures as test
easures (appropriate for internal quality improvement only)
the final set (2). After the peer review and public comment
riod, the writing committee reviewed and discussed the
mments received, and further refinements were made in the
ble 4. Associated Guidelines and Statements
ird Report of the National Cholesterol Education Program (NCEP), Expert
nel on Detection, Evaluation, and Treatment of High Blood Cholesterol in
ults (ATP III) (18)
e National Institutes of Health: National Heart, Lung, and Blood Institute:
tional High Blood Pressure Education Program (19)
C/AHA 2002 Guideline Update for the Management of Patients With
ronic Stable Angina (20)
blic Health Service: Treating Tobacco Use and Dependence Clinical
actice Guideline 2008 Update (21)
C/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery
2)
C/AHA 2007 Focused Update of the Guidelines for the Management of
tients With ST-Elevation Myocardial Infarction (23)
C/AHA 2007 Guidelines for the Management of Patients With Unstable
gina and Non–ST-Segment–Elevation Myocardial Infarction (24)
A Evidence-Based Guidelines for Cardiovascular Disease Prevention in
omen: 2007 Update (25)
A/SCAI 2007 Focused Update of the Guidelines for Percutaneous Coronary
tervention (26)
CF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR 2008 Appropriateness Criteria
r Stress Echocardiography (27)
CF/ASNC Appropriateness Criteria for Single-Photon Emission Computed
mography Myocardial Perfusion Imaging (28)
CF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR Appropriateness Criteria for
rdiac Computed Tomography and Cardiac Magnetic Resonance Imaging (29)
ACC indicates American College of Cardiology; ACCF, American College of
rdiology Foundation; ACEP, American College of Emergency Physicians; ACR,
erican College of Radiology; AHA, American Heart Association; ASE,
erican Society of Echocardiography; ASNC, American Society of Nuclear
rdiology; NASCI, North American Society for Cardiovascular Imaging; SCAI,
ciety for Cardiac Angiography and Interventions; SCCT, Society of Cardio-
scular Computer Tomography; SCMR, Society for Cardiovascular Magnetic
sonance; and SIR, Society for Interventional Radiology.easure set.. ACCF/AHA/AMA–PCPI 2011
oronary Artery Disease and
ypertension Performance Measures
.1. Target Population and Care Period
he target population for the outpatient measures consists of
tients with diagnoses of either CAD or hypertension. For
rposes of this document, the outpatient care period is
fined as the care provided in an outpatient setting within the
me period under evaluation—usually 1 year. These mea-
res are intended to assess the management of the care for
tients with CAD or hypertension at the practitioner level in
ambulatory-care setting for the primary purpose of quality
provement.
.2. Alignment With Existing
easure Sets and National Guidelines
he writing committee made every effort to harmonize these
rformance measures with similar metrics in other ACCF/
HA/AMA–PCPI performance measures sets. An example
this is the harmonization of the lipid-lowering measure in
is set with that in the ST-elevation myocardial infarction/
n–ST-elevation myocardial infarction set that specifies the
e of statin drugs as opposed to any lipid-lowering agent
a). In addition, the writing committee was aware that the 3
inical practice guidelines on which these measures are
rgely based were also at various stages of being updated,
t the writing committee decided to proceed with this
vised measures set without waiting for the final release of
e guideline updates. The guidelines in question are the
ighth Report of the Joint National Committee on Prevention,
etection, Evaluation, and Treatment of High Blood Pressure
NC 8), a forthcoming ACCF/AHA practice guideline on
able ischemic heart disease, and the guidelines of the
holesterol Education Project’s Adult Treatment Panel IV.
he writing committee’s decision to proceed was based on
e following considerations:
The CAD and hypertension performance measures set
originally was developed in 2005 and was due for updating
in 2008. Because the ACCF/AHA stable ischemic heart
disease practice guideline, the Cholesterol Education Proj-
ect’s Adult Treatment Panel IV, and the JNC 8 guidelines
are projected to be published in late 2011 or early 2012, the
writing committee felt that waiting would result in an
undue delay in the release of the present update. The
writing committee believed that a pragmatic approach to
this situation was needed, even though the more linear
approach of waiting for the guidelines to be published
before developing the measures had methodological appeal.
Members of the writing committees, who are developing
the guideline updates, were selected as members of this
writing committee to informally facilitate alignment of the
guidelines and the measures. These members are Eduardo
Ortiz (JNC 8), John Spertus (ACCF/AHA stable ischemic
heart disease practice guideline), and David Goff (Choles-
terol Education Project’s Adult Treatment Panel IV).
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July 12, 2011:316–36 Performance Measures for CAD and HypertensionThe writing committee focused on developing measures in
areas where the level of evidence was the strongest, thus
minimizing the risk that the measures would be out of
alignment with updated guidelines.
.3. Measures Related to Medication Use
he writing committee gave careful consideration to the types of
ble 5. Comparison of 2005 and 2011 Coronary Artery Disease
2011 Measure 2005 Measure Change
ronary
ery
ease
1. Blood pressure
control
Blood pressure
measurement
It is now an
intermediate out
measure.
2. Lipid control ● Lipid profile
● Drug therapy for
lowering LDL
cholesterol
New measure c
lipid profile with
therapy for lowe
LDL cholesterol.
3. Symptom and
activity
assessment
Symptom and activity
assessment
This measure no
requires simulta
assessment.
4. Symptom
management
No measure for 2005 This is a new m
5. Tobacco
cessation and
intervention
Smoking cessation
(assessment)
The new measu
requires 2 action
assessment and
intervention.
6. Antiplatelet
therapy
Antiplatelet therapy The description
numerator have
modified.
7. Beta-blocker
therapy: prior MI
Beta-blocker therapy:
prior MI
The description
denominator hav
modified.
8. ACE inhibitor/ARB
therapy: diabetes
or left ventricular
systolic
dysfunction (LVEF
40%)
ACE inhibitor/ARB
therapy
The description
denominator hav
modified.
9. Cardiac
rehabilitation
patient referral
from an
outpatient setting
No measure for 2005 This is a new m
Screening for
diabetes
This measure w
retired.
pertension
1. Blood pressure
control
● Plan of care
● Blood pressure
measurement
Both original me
were combined
single measure
become an inter
outcome measu
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor
ntricular ejection fraction; and MI, myocardial infarction.edication use measures that would be developed for the aseasures set. The discussion centered on whether to include
ly measures of prescription of medications or to develop
easures of optimal dosing and patient adherence as well.
.3.1. Prescription Alone Versus Optimal Dosing
developing its blood pressure measures, the writing com-
ittee recognized the need to strike a balance between
ypertension Performance Measures
Rationale
The writing committee believed that the original measure, which relied on a plan of
care, failed to account for an adequate “intensity” of effort to control blood
pressure. The current measure therefore targets established goals and makes
accommodations for patients with refractory hypertension by specifying that
2 medications be used. The management plan may include the prescription of
2 antihypertensive medications, referral for consideration of coronary
revascularization, or referral for additional evaluation or treatment of anginal
symptoms.
The writing committee believed that the evidence favoring the use of statins as a
specific intervention was sufficient to explicitly recommend this treatment. This was
based on the higher risk associated with this population and the demonstrated
effectiveness of statins in reducing risk of adverse outcomes.
The control of symptoms at patients’ desired level of activity is the primary reason
patients with chronic stable angina often seek care and is a highly relevant
outcome. Simultaneous assessment of symptoms and activity provides a more
comprehensive view of patient status and improves on the previous version of the
measure(s) in that it requires the evaluation of both level of activity and presence
of anginal symptoms, because patients may accommodate increasing angina by
decreasing their physical activities.
The writing committee recognized a significant gap in measures addressing critical
patient-centric outcomes for chronic stable CAD care and effective management of
ischemic symptoms.
There is good evidence that tobacco screening and brief cessation intervention
(including counseling and pharmacotherapy) in the primary-care setting is
successful in helping tobacco users quit.
Use of antiplatelet therapy has been shown to reduce the occurrence of vascular
events in patients with CAD, including MI and death.
ACCF/AHA guidelines have shown that for hospitalized patients with reduced
ejection fraction, ACE inhibitors or ARBs and beta-blocker therapy should be
continued.
Recent national registry data indicate that the use of ACE inhibitors or ARBs in
eligible patients without documented contraindications or intolerance remains
suboptimal, especially in the outpatient setting.
Cardiac rehabilitation programs remain underused. The writing committee
recognized a significant gap in this area.
Although screening for diabetes in the chronic stable CAD patient population is
important, the measure was found to be difficult to implement and therefore was
not widely used. Additionally, new screening guidelines are forthcoming, in which
the recommendations for screening may change significantly. The Diabetes Work
Group met in 2009, and the Chronic Stable Coronary Artery Disease Writing
Committee defers this measure to that group for their consideration.
The measures were combined to capture both patients who have their blood
pressure controlled and those who do not have their blood pressure controlled but
have their treatment regimen adjusted as a result. The management plan may
include either the prescription of 2 antihypertensive medications, referral for
consideration of coronary revascularization, or referral for additional evaluation or
treatment of anginal symptoms.
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Performance Measures for CAD and Hypertension July 12, 2011:316–36izing the likelihood that promoting a strict standard for
timal dosing would lead to adverse, unintended conse-
ences related to overtreatment. Overtreatment can result in
isodes of hypotension with associated orthostatic symp-
ms, frank syncope, and injuries from falls. The writing
mmittee also considered the difficulties of capturing spe-
fic doses of medications and of assessing whether dosing
as optimal. The writing committee also was concerned
out broadly implementing measures of medication dosing
cause of the challenges of capturing large numbers of
tential contraindications and adverse effects of individual
edications.
In addition, requiring optimal dosing could decrease some
tients’ access to care and create or worsen healthcare dispar-
es. With the requirement that only patients attaining blood
essure targets would successfully meet the measure, physi-
ans would have an incentive not to accept into their practices
tients with refractory blood pressure or with difficult-to-
ntrol CAD symptoms. This was a concern because the
sulting “lower scores” would reflect poorly on the physician,
using some to dismiss such patients from their practices. The
riting committee also recognized that using medication pre-
ription alone, as opposed to patients’ filling their prescriptions,
a performance measure could potentially be viewed as
ndoning undertreatment. Nevertheless, current healthcare re-
rds, which often do not link to pharmacy data, render data on
tient pharmacy refills impractical to collect. Finally, the
riting committee recognized that physicians could use multiple
edications at suboptimal doses and that the current measure
ould give those physicians “credit” for meeting the measure,
en if patients’ blood pressures remained elevated. Neverthe-
ss, balancing these considerations with concerns about feasi-
lity, unintended consequences such as adverse selection, and
ble 6. ACCF/AHA Attributes of Performance Measures
Consideration Attribute
eful in improving patient
tcomes
Evidence based
Interpretable
Actionable
easure design Denominator precisely defined
Numerator precisely defined
Validity type
● Face*
● Content†
● Construct‡
Reliability
easure implementation Feasibility
● Reasonable effort
● Reasonable cost
● Reasonable time period for collection
erall assessment Overall assessment of measure for inclusion
in measurement set
*The measure intuitively seems to capture what it is intended to capture.
†The extent to which the items comprehensively capture the domain they
e intended to measure.
‡The extent to which the measures correlate with other methods of
antifying the underlying construct.
Adapted from Normand et al. (39).ethodological difficulties, the writing committee ultimately clcided to measure the medication prescription but not optimal
sing.
.3.2. Medication Adherence
he writing committee debated whether physician quality
as better assessed through measures of medication prescrip-
on or patient adherence to prescribed medication. The major
jection to the use of patient adherence as a measure of
ysician quality is that, although prescribing physicians
ve some influence on patient choices, adherence is largely
t in the individual physician’s locus of control. Health
surance pharmacy benefit designs, including formularies
d copays, play important roles in patient decisions to
here to prescribed drug regimens (40,41). Ultimately,
cause patient autonomy is the overriding ethical and
agmatic principle governing the patient-physician relation-
ip, the patient is free to decide whether to take medications
prescribed. Similar to the above concern with optimal
sing, a measure of patient adherence could cause physi-
ans to avoid caring for patients with a history of nonadher-
ce or a perceived likelihood of being nonadherent. This, in
rn, could reduce access to care for such patients, with
lnerable populations being at particular risk.
Another major concern is that reliable information on
tient adherence is often difficult and expensive to obtain.
ewer methods of electronic transfer of information from
armacies may make measurement of adherence more
asible in the future. Once these linkages are standard
actice, adherence measurement may become a valuable
ality-improvement and patient-management tool for the
ysician, but, because of the difficulty of capturing medica-
on sampling and low-cost, generic prescriptions that are
lled outside of a pharmacy benefit plan, the data may never
hieve the level of quality required for a publicly reported
easure.
Although the writing committee decided that medication
herence would not be included as a measure of individual
ysician performance, it believed that measures of adher-
ce, such as those included in HEDIS (Healthcare Effective-
ss Data and Information Set), could be used at the health
an, employer, or health system levels as effective quality-
provement tools. The writing committee believed that
alth plans and employers have more potential influence on
herence, through improved mechanisms to follow up on
filled prescriptions and through economic incentives—for
ample, removing copays for antihypertensive medications.
addition, these larger organizations have the resources to
eate effective disease management and case management
ograms (40,42–44), which have appeared to improve med-
ation adherence.
.4. Outcome Measures
he outcome measures selected were the subject of intense
bate within the writing committee, which sought to ad-
nce the utility of the measures and to maintain consistency
ith our existing standards for public reporting (2,11).
easures were selected by writing committee consensus and
ere carefully judged, with the goals of moving toward more
inically important outcomes (e.g., symptom control for
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July 12, 2011:316–36 Performance Measures for CAD and HypertensionAD) and adding process measures (e.g., referral to cardiac
habilitation [CR]), given that evidence of the relationship of
ocess measures to important clinical outcomes has accrued.
he writing committee was also sensitive to the pitfalls of
ing “intermediate outcomes,” such as blood pressure and
w-density lipoprotein cholesterol goals, in isolation, as
easures of quality (45–47). The writing committee evalu-
ed the inclusion of measures related to death, cerebrovas-
lar accident, and other life-altering events but believed that
eir low incidence, variability, or uncertain relationship to
eexisting risk factors (i.e., inadequate risk adjustment)
ecluded their inclusion at this time (48). The measures
lected are based on existing guidelines, and the majority are
sociated with Class I recommendations (e.g., CR, antiplate-
t therapy) and with Level A evidence (e.g., angiotensin-
nverting enzyme inhibitor/angiotensin II receptor blocker
erapy, beta-blocker therapy).
The writing committee designed individual measures to
pture unique information that allows independent analysis
t developed combined measures when independent report-
g of outcomes could lead to misinterpretation given the
rrent state of understanding of the impact on these out-
mes of variables such as risk factors, case mix, and
idence. It is hoped that the current set of measures will
ovide contemporaneous information as the evidence base
velops and thus permit future measure enhancement in this
ea. The writing committee continued to support denomina-
r exceptions for many of the measures with appropriately
tegorized documentation of the reason for the exception.
he development of large databases of appropriate exceptions
essential and will be promoted by use of these measures as
signed. This information will be critically important, when
ed with risk-adjustment models, to enable public reporting
independent, clinically important outcome measures that
ovide an interpretable and accurate description of individ-
l practice.
. Discussion of Changes to the
005 Measures Set
he current measures sets (Table 2) represent significant
partures from the first ACC/AHA/AMA–PCPI CAD/hy-
rtension performance measures. The writing committee
amined the 9 CAD measures and 2 hypertension measures
the original 2005 set and considered updated guideline
commendations, field-testing data, and implementation ex-
riences to determine whether any of the measures should be
vised or retired. The writing committee also discussed
hether measures with very high rates of compliance should
main in the measure set to emphasize their clinical impor-
nce, even though provider performance on them appears to
ve “topped out.”
Changes in the current measures set include both revisions
prior measures and the addition of new measures. In
dition, one measure from the CAD set is being retired. The
riting committee’s rationale for making these changes and
r not adding certain measures of perceived importance will
discussed in the following sections of this document. re.1. Retirement of 2005 Coronary
rtery Disease and Hypertension Measures
nly one measure (the CAD measure “screening for diabe-
s”) from the CAD and hypertension measures set is being
tired, and none was believed to have topped out.
.1.1. Retirement of Coronary Artery Disease Measure:
creening for Diabetes
he writing committee decided to retire the CAD measure
creening for diabetes” because of several factors:
The logistical difficulty in screening for diabetes, requiring
the patient to return for laboratory testing for either a
fasting blood glucose test or a postchallenge 2-hour glu-
cose tolerance test
Lack of clarity about the evidence supporting a 1-year
interval for testing for diabetes in patients with CAD, with
the American Association of Clinical Endocrinologists
guideline in diabetes (2007) rating the evidence as Level C
User reports of challenges in implementing the diabetes
screening measure
The writing committee recognized the significance of
abetes as a comorbidity in patients with CAD and also
cognized that the validity of the diabetes-related measure in
e current set (angiotensin-converting enzyme inhibitor or
giotensin II receptor blocker therapy—diabetes or left
ntricular systolic dysfunction) depends on the accurate
entification of the prevalence of diabetes in the denominator
pulation. Additionally, the writing committee noted that
e 2010 American Diabetes Association “Standards of Med-
al Care in Diabetes” addressed the difficulty in screening for
abetes in that they now state that a properly validated
moglobin A1c assay can be used to diagnose diabetes at a
lue 6.5% (49). The use of the hemoglobin A1c as a
reening test for diabetes could also be expected to make it
gnificantly easier to identify such screening in the medical
cord—a major challenge faced during efforts to implement
e original measure.
After a thorough discussion of all of these considerations,
e writing committee decided to remove this measure from
e CAD set and to defer further discussion of diabetes
reening measures to the NCQA/AMA–PCPI Joint Diabetes
xpert Panel.
.2. New Performance Measures in
his Update
ew performance measures were created to reflect the newest
ideline recommendations and address significant gaps in
re. In addition, the writing committee explored the devel-
ment of outcome, group- or system-level, overuse, com-
site, and bundled measures.
.2.1. Coronary Artery Disease: Symptom Management
reatment of CAD has 2 complementary objectives: to
duce the risk of death and to control anginal symptoms.
linical events such as death or myocardial infarction are rare
lative to the frequency of daily symptoms and functional
mitations experienced by many patients. Because of the
lationship between symptoms of ischemic heart disease and
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Performance Measures for CAD and Hypertension July 12, 2011:316–36e level of patient activity, the writing committee required
multaneous activity and angina assessment as a patient-
ntered process measure that is directly related to a mean-
gful outcome. This pairing of symptom and activity assess-
ent is necessary because patients may modify their activity
lessen anginal symptoms. Thus, a worsening in symptom
ntrol might manifest itself as more angina at a similar
ount of activity, similar or less angina at a lower level of
tivity, or both. Moreover, patients’ CAD can change over
me, and the sequential evaluation of symptoms is a neces-
ry means of optimizing patients’ treatment plans. The
riting committee considered the challenges inherent in
easuring patient-reported outcomes, including the limited
ter-rater reliability of physician-performed functional as-
ssments such as the Canadian Cardiovascular Society
lassification. Patient-centered, disease-specific health status
estionnaires can overcome this problem, but such methods
e not used routinely in patient care because of the redesign
patient workflow that would be required and the fact that
e current reimbursement system does not incentivize such
forts. Nevertheless, systems for administration and scoring
ist and could be further refined to meet a perceived need for
e systematic collection of these data. Several commonly
ed and validated tools are provided as examples of how
gina could be evaluated and documented. A narrative
sessment of symptom and activity status documented in the
art can also satisfy the numerator for this measure but will
ake extraction from electronic medical records systems
fficult.
Extensive discussion of the frequency of assessment was
so undertaken by the writing committee, and, although it is
ear that it might be appropriate to assess symptoms and
tivity for every visit in which a CAD diagnosis was billed,
e writing committee felt most comfortable requiring that
is be reported at least once within a 12-month period.
The writing committee recognized a significant gap in
easures addressing patient-centered outcomes of chronic
able CAD care. The symptom management measure helps
close this gap by requiring the collection of information
cessary to assess the patient’s functional status and by
omoting intensification of therapeutic interventions when
mptoms are not adequately controlled. In choosing this
easure, the writing committee recognized that patients who
ve frequent anginal symptoms report worse quality of life,
ve worse survival rates, incur higher costs, and are more
ssatisfied with their care than those with less severe
mptoms (50–56). Given the challenges in documentation
lated to the measure, the writing committee considered
aking symptom management a quality-improvement–only
easure. The writing committee believed this was not appro-
iate, however, because of the importance of effective
anagement of ischemic symptoms. Accordingly, when
mptom changes are identified during a visit, a plan to
dress the change in status should be documented. That
anagement plan may include the prescription of 2 anti-
pertensive medications, referral for consideration of coro-
ry revascularization, or referral for additional evaluation or
eatment of anginal symptoms. If a plan for control of angina
nnot be implemented, then a medical-, system-, or patient- shlated reason should be noted as outlined in the PCPI’s
ceptions methodology (17). The writing committee realizes
at complete elimination of symptoms is not always possi-
e, so this measure prioritizes symptom management and the
tient’s experience as the primary goal of the therapeutic
counter. In addition, there was discussion of other aspects
managing chronic CAD patients who report a change in
mptoms, including lifestyle interventions, assessment of
edication adherence, patient education, and evaluation for
rdiac or noncardiac contributors (arrhythmias, depression,
d heart failure). The writing committee believed, however,
at these other aspects of care, though important parts of the
erapeutic approach, are so broad or complex as to preclude
clusion as measures for the chronic management of CAD.
.2.2. Coronary Artery Disease: Cardiac Rehabilitation
atient Referral From an Outpatient Setting
R is underutilized, despite evidence that it improves quality
life, reduces modifiable cardiovascular risk factors, en-
nces adherence to preventive medications, and lowers the
sks of morbidity and mortality (57–74). Suaya et al (70)
alyzed outcomes from 601,099 Medicare beneficiaries and
und that only 13.9% of eligible patients enrolled in CR after
yocardial infarction, noting significant geographic variation
referral rates and lower use in women, nonwhites, older
tients, and those also receiving Medicaid, despite a 21% to
% reduction in 5-year mortality rate in those who partici-
ted when compared with nonparticipants (71). More re-
ntly, the PINNACLE Program of the American College of
ardiology’s National Cardiovascular Data Registry (NCDR)
und that only 18.1% of eligible patients were referred to CR
7). For these many reasons, the writing committee recog-
zed a significant opportunity for improvement and included
e NQF-endorsed referral to CR measure in this set.
During the public comment period, reviewers asked that
e writing committee consider adding an accompanying
easure that captures whether the referral to CR is followed
enrollment in CR, the ultimate desired outcome. The
riting committee recognized that factors affecting enroll-
ent and completion of CR are complex and involve issues
yond the control of referring practitioners, such as inade-
ate insurance coverage (including benefit design features
ch as high copayments), lack of available programs in
any urban and rural areas, transportation problems, and
mited patient education and motivation to participate. Per-
rmance measures tracking enrollment and completion of
R are included in the 2007 American Association of
ardiovascular Pulmonary Rehabilitation/AHA Performance
easures on Cardiac Rehabilitation (7) and were written to
courage performance-improvement activities by CR pro-
ams. In addition, during the NQF endorsement process, the
merator statement for the CR measure was revised to
pand standards of practice for CR programs (7a). Important
ong these is care coordination, which recognizes that CR
ograms should communicate with referring providers not
ly about medical issues, but also about completion of the
R program. Future iterations of CR performance measures
ould include enrollment and completion measures, after
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July 12, 2011:316–36 Performance Measures for CAD and Hypertensionrther studies have clarified responsibilities, defined excep-
ons, and evaluated feasibility.
.3. Revised Measures in This Update
our measures from the CAD set and 1 measure from the
pertension set were modified to incorporate results from
eld-testing projects and to address inadequacies in the
iginal measures.
.3.1. Combining Hypertension Measures:
lood Pressure Measurement and Plan of Care
he writing committee concluded that the ACCF/AHA/
MA–PCPI hypertension measures should be modified and
mbined into one measure that would reflect not only blood
essure measurement, but also an evidence-based, clinically
portant intermediate outcome that would be correlated with
ture reductions of clinical morbidity, complication, hospi-
lization, and mortality rates. This intermediate outcome
flects the writing committee’s recognition that blood pres-
re targets for specific populations are still being refined
5). For the hypertension measure set, the writing committee
ose a denominator statement of all patients aged 18 years
ith hypertension; for the CAD set, the denominator is all
tients aged 18 years with a diagnosis of CAD. The
merator was defined as all patients with a blood pressure
140/90 mm Hg, or all patients with a blood pressure of
140/90 mm Hg who were prescribed 2 antihypertensive
edications during the most recent office visit during the
eatment period. The writing committee considered modify-
g the target blood pressure for patients with diabetes.
lthough earlier guidelines—JNC 7 2004 (19), American
ssociation of Clinical Endocrinologists 2007 (75), and
merican Diabetes Association 2010 (49)—have suggested a
ood pressure target 140/90 mm Hg for patients with
abetes, evidence from the ACCORD (Action to Control
ardiovascular Risk in Diabetes) trial (45) and INVEST
nternational Verapamil SR/Trandolapril Study) (76) indi-
tes that a blood pressure target 140/90 mm Hg may
ovide a less favorable benefit-risk ratio in patients with
abetes than had been previously thought. The writing
mmittee defers further consideration of blood pressure
rgets in patients with diabetes to the NCQA/AMA–PCPI
int Diabetes Expert Panel for further clarification.
The writing committee emphasizes the importance of the
ality of the data used to make clinical decisions. In the case
the hypertension performance measure, proper technique
d preparation for obtaining the blood pressure value used in
e measure are most important. Validated blood pressure
onitors, whether used for home monitoring or in the
edical office setting, and when used with proper technique,
cluding an appropriate period of rest beforehand (5 to 10
in), will yield blood pressure readings that correlate well
ith the standard manual technique.
.3.2. Coronary Artery Disease: Smoking Cessation
he writing committee agreed that tobacco use remains a
gnificant modifiable risk factor for CAD and that evidence
ows that screening and brief cessation intervention (coun-
ling, pharmacotherapy, or both) at the point of care can Ccrease overall tobacco abstinence rates (21,77,78). Further-
ore, an opportunity exists to improve present levels of
reening and intervention. The writing committee discussed
e frequency of measurement, with some advocating that
reening and intervention be treated as a vital sign and be
rformed at every visit, whereas others were concerned that
cessive documentation requirements would minimize the
portance of screening and intervention, with tobacco
reening devolving to just another activity for the physician
check off in the medical record (21,78). The writing
mmittee also recognized the difficulty of measuring the
ality of specific types of interventions and their influence
tobacco abstinence rates. The writing committee, there-
re, elected to keep the requirement to 1 screening and
tervention per 1-year measuring period.
Eventually, the writing committee believes this process
easure could be replaced by documentation of tobacco-free
tes. The writing committee decided that developing a
easure of tobacco-free rates was premature at this juncture
cause of socioeconomic and geographic disparities and the
fficulty of actually determining ongoing rates of tobacco use
iven the high recidivism rate after smoking cessation).
.3.3. Coronary Artery Disease: Lipid Control
he lipid control measure also underwent significant revision.
he original measure, which emphasized achieving a low-
nsity lipoprotein target and was indifferent to the drugs
ed to achieve it, was retired. It was replaced with a measure
at emphasizes statin use. This decision was predicated on
erging insights that statin therapy specifically results in a
latively constant relative risk reduction that is clinically
portant in a high-risk population, such as those with
tablished CAD. In contrast, the data supporting specific
pid targets (a distinct concept from higher-dose statins that
e associated with additional clinical benefits) are much
eaker. Given the absence of data on the clinical benefit of
me nonstatin medications that reduce cholesterol (46,47),
e writing committee believed that the weight of evidence
pported a specific, statin-based performance measure.
.3.4. Hypertension and Coronary Artery Disease:
lood Pressure Control
he link between hypertension and the development of
rdiovascular events is well substantiated. Individuals with
gh underlying cardiovascular risk (e.g., those with estab-
shed atherosclerotic disease, diabetes mellitus, chronic kid-
y disease, or multiple cardiovascular risk factors) have the
eatest absolute risk of new cardiovascular events attribut-
le to uncontrolled hypertension.
We chose 140/90 mm Hg as the threshold for hypertension
ntrol in these performance measures because it is the
commended blood pressure goal in JNC 7 both for individ-
ls with and without established cardiovascular disease (19).
s noted previously, the status of specific blood pressure
rgets for patients with diabetes and hypertension is cur-
ntly in flux despite the JNC 7 recommendation of 130/80
m Hg as a goal (19). Arguments also have been made to
pport a general goal of 130/80 mm Hg for patients with
gh cardiovascular risk, including patients with established
AD (79,80). Nevertheless, no clinical trial directly com-
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sease patients treated to different blood pressure targets.
ome clinical trials in which specific antihypertensive drug
erapies were given to individuals with CAD or high
rdiovascular disease risk who had blood pressures140/90
m Hg have shown beneficial results (81–83), but other trials
ve had negative or equivocal findings (84–87). Although
is heterogeneity in the published literature justifies the use
the less strict 140/90 mm Hg threshold in these perfor-
ance measures, lower blood pressure targets may be appro-
iate for some patients with CAD or other conditions. At this
int, however, it is unclear how such patients could be
liably identified for purposes of performance measurement.
The writing committee recognized that hypertension treat-
ent decisions generally should be based on the average of
ultiple readings and that for many patients there is a role for
ood pressure measurement outside the clinician’s office
.g., home blood pressure monitoring or ambulatory blood
essure monitoring). Whether different goals should be used
interpreting blood pressures obtained at home is an issue
at has not been clearly resolved, so the writing committee
d not specify a different blood pressure threshold for
easurements obtained outside the office (79).
The writing committee engaged in a protracted and de-
iled discussion of the blood pressure value to be used in
lculating this measure because the clinician may be looking
multiple home readings, the results of ambulatory blood
essure monitoring, values obtained in the office, or some
mbination of all of these. It is difficult to provide one
erational definition for use in a performance measure that
dicates whether blood pressure measurements that may be
ailable within a patient’s medical record should be aver-
ed to indicate how well the blood pressure is controlled.
ltimately, the writing committee settled on requiring the
ovider to specify at each visit the blood pressure reading
at was used in clinical decision making. When a clinician
es the mean of multiple readings to determine whether a
tient has controlled blood pressure, this value can be used
the specified value in the performance measure.
Achievement of the hypertension performance measures
quires that the blood pressure decrease to 140/90-mm Hg
reshold or that 2 antihypertensive medications are pre-
ribed in the absence of a medical-, patient-, or healthcare
stem–related reason that justifies not doing so. (For pur-
ses of this measure, the individual components of combi-
tion medications are counted separately.) The drug-
escription measure was selected with the recognition that
easures used for accountability and reporting that are solely
sed on outcomes—here, blood pressure control—may not
eld informative comparisons when risk adjustment is not
rformed and that it is not feasible to develop and broadly
ply robust risk-adjustment models at this time. (The writing
mmittee nevertheless believed that the proportion of pa-
ents with controlled blood pressure remains of interest and
ould be tracked by providers separately for quality-
provement purposes.) In addition, the trials that demon-
rated the cardiovascular benefits of blood pressure lowering
ve typically used 2 medications in the more intensively steated groups, especially in participants who did not meet the
ial-specific blood pressure control goals.
A limitation to the hypertension performance measures
esented here is that their scope includes only blood pressure
ntrol or the prescription of 2 drugs. The writing commit-
e recognizes that many other necessary aspects of hyper-
nsion care are not part of these measures. These include but
e not limited to counseling and other interventions to
omote dietary modification, weight loss, physical activity,
lf-monitoring, care plan adherence, and appropriate follow-
. The writing committee did not leave these topics out of
e measures because we viewed them as less important than
ug therapy. Rather, they are less readily measured with
isting data sources, and the satisfaction of counseling
quirements for a performance measure does not provide any
dication about the quality of the counseling interactions
ovided by clinicians. We also recognize that appropriate
cognition and treatment of concomitant risk factors (e.g.,
oking, dyslipidemia, related comorbidities such as kidney
sease) are important components of the care of patients with
pertension, but they are not within the scope of these
easures.
.3.5. Coronary Artery Disease: Antiplatelet Therapy
he writing committee chose to revise the 2005 antiplatelet
erapy measure to include only the prescription of clopi-
grel or aspirin in the numerator. The prior measure allowed
r prescription of any antiplatelet agent to be counted in the
merator. The rationale for the change is that the guidelines
which this measurement set is based (88) state that aspirin
ould be started at 75 to 162 mg per day and continued
definitely in all patients unless contraindicated (Class I,
evel of Evidence: A) and that clopidogrel can be used when
pirin is absolutely contraindicated (Class IIa, Level of
vidence: B). No other antiplatelet agents are recommended.
The writing committee recognizes that a new antiplatelet
ent, prasugrel, has been approved by the U.S. Food and
rug Administration for use in acute coronary syndromes and
at some patients with chronic stable coronary disease will
on this agent. The writing committee concluded, however,
at prasugrel could not be added to the antiplatelet measure
til such time as the drug is recommended in the pertinent
actice guideline. In the interim, patients on this agent can be
cluded from the denominator as a medical exception. The
me reasoning will hold for other antiplatelet agents cur-
ntly under development that may receive Food and Drug
dministration approval in the future.
.4. Potential Measures Considered But Not
cluded in This Update
he writing committee considered several other potential
easures. For various reasons they were determined to be
appropriate for inclusion in the measure set.
.4.1. Coronary Artery Disease:
veruse of Stress Testing
an attempt to address efficiency in the management of
AD, the writing committee considered a measure of 1
ress test per year in patients with stable CAD. This measure
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July 12, 2011:316–36 Performance Measures for CAD and Hypertensionas selected because of a belief among some of the writing
mmittee members that excessive stress testing in patients
hose symptom status had not changed was a significant
sue. To investigate this hypothesis, AMA–PCPI staff re-
ewed Medicare claims data and found that, in the absence
an acute coronary syndrome, few patients with CAD had
1 stress test in a given year. This information is available at
ttp://www.ama-assn.org/apps/listserv/x-check/qmeasure.
i?submitPCPI (4a).
Additionally, the writing committee took note of the
CCF’s separate efforts to develop appropriate use criteria
r diagnostic imaging (89). Furthermore, in a study per-
rmed with United Healthcare, gaps were identified in the
propriate application of diagnostic imaging as measured by
ese criteria (29). As the current measures set was being
veloped, the ACCF submitted imaging efficiency measures
NQF that were based on its appropriate use criteria and that
d been successfully piloted in the United Healthcare study
0). Finally, the writing committee is aware that the ACCF
preparing a document that will delineate the methodology
is using in developing measures of quality and appropri-
eness in the use of technology and that will incorporate the
sults of its efficiency measures work. The writing commit-
e agrees with the observation made in the ACCF/AHA
atement on efficiency measures that appropriate use criteria
e well suited as the basis of such measures because they
corporate quality and appropriateness (91). Because of the
fficulty encountered in constructing an efficiency measure
d because of the work being done by ACCF in this
portant area, the writing committee decided to defer for
w the further development of diagnostic efficiency mea-
res, pending the results of the ACCF’s efforts.
.4.2. Measures Related to Appropriate Use of
ercutaneous Coronary Intervention,
hysiological Testing Before Percutaneous
oronary Intervention, and Treatment
election for Revascularization
he writing committee determined that addressing appropri-
e use of percutaneous coronary intervention (PCI) is beyond
e scope of this document. The ACCF/AHA/AMA–PCPI/
CQA PCI Writing Committee will specifically address
propriate use of PCI and physiological testing before PCI
d will evaluate both overuse and underuse of PCI. Al-
ough overuse will most readily be assessed through proce-
ral registries, such as the ACC’s NCDR CathPCI Registry,
deruse will require the assessment of symptoms among
tients with stable ischemic heart disease. With more expe-
ence from the currently proposed symptom management
easure and the input from the ACCF/AHA/AMA–PCPI/
ociety for Cardiovascular Angiography and Interventions/
CQA PCI Writing Committee, we anticipate being able to
ovide measures for the appropriate use of PCI in subse-
ent measurement sets.
.4.3. Measures Related to Shared Decision Making
hared decision-making approaches have been advocated as a
ay to potentially increase patient commitment to long-term
herence to cardiovascular medications such as statins and mtihypertensive agents (92,93). Shared decision making,
cilitated by the use of structured decision aids, does appear
improve patients’ confidence in and satisfaction with
hatever decision they make about taking chronic medication
4). Nevertheless, the limited published data on the effects of
e use of decision aids on decisional outcomes, including
edication acceptance and adherence, have shown mixed
sults (95–99), partly because of inconsistent implementa-
on of the decision aid (100).
Patients’ perceptions of untreated risk severity and poten-
al benefits and harms of treatment depend heavily on the
ays in which risk information is conveyed (94). Expressing
tential treatment benefit in terms of relative (versus abso-
te) risk reduction has been associated with higher accep-
nce of and adherence to statin therapy (101). Detailed
formation about potential adverse side effects of medica-
ons may tend to decrease initial medication acceptance, no
atter how it is expressed. Accuracy of patients’ risk percep-
ons may be best improved by using naturalistic frequencies
d graphic illustrations (93,102).
Thus far, no care guidelines policy groups have set forth
idence-based recommendations or proposed any metrics
r evaluating shared decision making, although international
andards are under development (103,104). For these rea-
ns, the writing committee is not including any provision
lated to shared decision making for the management of
AD and hypertension.
.5. Testing and Research
esting is a requirement for all performance measures before
eir use in public reporting or pay-for-performance programs
05,106), and NQF will not fully endorse measures that have
t been comprehensively tested (78). The AMA–PCPI has
blished a document delineating the thorough testing proto-
l to which all of its measures will be subjected (107). All of
e new measures in this set will be tested according to that
otocol. The writing committee recommends that these
easures not be broadly used for accountability purposes
til this testing is complete.
Additionally, the writing committee recommends that
e process measures in this set be systematically studied
ith respect to their effects on clinical, financial, and
tient satisfaction outcomes. Of particular note in this
gard is the blood pressure control measure in the
pertension set, which was the subject of much discus-
on during the writing committee deliberations and during
e public comment period. The writing committee encour-
es research into the effect of this measure on the
escription of optimal or maximally tolerated doses of
tihypertensive medications and on ultimately achieving
ood pressure control targets; such research should use
propriate risk adjustment and evaluate both desired
tcomes and unintended consequences. All arguments
out these issues remain highly theoretical until these
rts of objective data are obtained.
Another measure of particular interest with respect to its
tential impact on outcomes is the symptom and activity
sessment measure in the CAD set. Implementation of this
easure is likely to identify patients whose angina symptoms
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Performance Measures for CAD and Hypertension July 12, 2011:316–36e not adequately controlled, leading to additional diagnostic
d therapeutic interventions. These interventions, in turn,
ay have a positive impact on angina-related quality of life,
well as morbidity rate, mortality rate, and costs. Under-
anding the balance of these various outcomes in different
pulations will have obvious utility for policy makers,
ysicians, and especially patients.
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